Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aknicare Cleanser is a topical dermatological product used as an adjuvant therapy for the treatment of mild to moderate acne vulgaris. It is a combination product containing triethyl citrate and pyruvic acid as its primary active ingredients. Triethyl citrate acts as a pro-drug that is hydrolyzed by bacterial lipases into citric acid, which lowers the skin's pH and inhibits the activity of *Cutibacterium acnes* (formerly *Propionibacterium acnes*). Pyruvic acid provides keratolytic properties, facilitating the exfoliation of the stratum corneum and preventing follicular occlusion and comedone formation. The product is typically used as part of a multi-step regimen alongside other Aknicare products and prescription treatments like adapalene to manage sebum production, inflammation, and bacterial colonization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Aknicare Cleanser.